Last reviewed · How we verify
NCT04177576: MPN-BIOCLOT
Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
trial testing 2 additional tubes of blood in Myeloproliferative Neoplasm in 397 participants. Completed in 26 January 2022.
26 January 2022
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 397 |
| Start date | 24 February 2020 |
| Primary completion | 26 January 2022 |
| Estimated completion | 26 January 2022 |
| Sites | 24 locations across France |
Drugs / interventions tested
- 2 additional tubes of blood — full drug profile →
Conditions studied
- Myeloproliferative Neoplasm — all drugs for Myeloproliferative Neoplasm →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Myeloproliferative Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive. Neutrophils can release their decondensed chromatin as a network of extracellular fibers named NET for "neutrophils extracellular trap". NETs are known to be procoagulant. Our main objective is to quantify NETs biomarkers expression in MPN patients and define if they could be used as prognostic factors in the outcome of thrombosis in these patients.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neutrophil Extracellular Traps in Tumor Metastasis: Pathological Functions and Clinical Applications.
Chen Q, Zhang L, Li X, Zhuo W. · · 2021 · cited 56× · PMID 34204148 · DOI 10.3390/cancers13112832 -
Neutrophil Extracellular Traps (NETs): Opportunities for Targeted Therapy.
Volkov DV, Tetz GV, Rubtsov YP, Stepanov AV, et al · · 2021 · cited 16× · PMID 34707894 · DOI 10.32607/actanaturae.11503 -
NETs - as predictors and targets of supportive therapy for cancer treatment.
Morawiec ML, Kubina R, Jabłońska E, Ratajczak-Wrona W, et al · · 2025 · cited 1× · PMID 41019086 · DOI 10.3389/fimmu.2025.1666261
Verify or expand the search:
- PubMed search for NCT04177576
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloproliferative Neoplasm
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06468033 — P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk · Phase 3 · recruiting
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
- NCT05745285 — Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care · NA · recruiting
- NCT06553638 — Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloprolif · active not recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04177576 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 6 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04177576.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing